Company & Sponsor Intelligence

Eisai Limited

Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.

Request enterprise analysis →

Indexed trials7

Recruiting1

Completed3

Countries5

Therapeutic footprint

alzheimersepilepsyparkinsons

Indexed studies

NCT07781345A Postmarketing Study of LEQEMBI in United Kingdom (UK) Participants With Alzheimer's Disease (AD)
alzheimers · United KingdomNOT_YET_RECRUITING

NCT01172379A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Safety, Tolerability and Efficacy of E2007 in Parkinson's Disease Patients With "Wearing Off" Motor Fluctuations and "On" Period Dyskinesias
parkinsons · CzechiaPHASE2

NCT01404169A 24-weeks, Multi-center, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Donepezil Hydrochloride in Chinese Subjects With Severe Alzheimer's Disease
alzheimers · ChinaPHASE3

NCT04257604A Study of Perampanel as Add-on Therapy in Adult and Adolescent Participants With Focal Seizures
epilepsy · COMPLETED

NCT00693017Efficacy and Safety of Adjunctive Zonisamide in Myoclonic Seizures Associated With Idiopathic Generalised Epilepsy
epilepsy · AustraliaPHASE3

NCT01546688A Study to Evaluate the Safety and Tolerability and Explore the Efficacy of Zonisamide as add-on Therapy in Elderly Patients With Refractory Partial Seizures
epilepsy · GermanyPHASE4

NCT00692003Adjunctive Zonisamide in Primary Generalised Tonic Clonic Seizures
epilepsy · AustraliaPHASE3

Intelligence layer updated: 2026-10-14 06:11:28.884102+00:00

Enterprise intelligence

Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.

Request comparative intelligence →